What is the share price of Rekvina Laboratories Ltd (VINRKLB) today?
The share price of VINRKLB as on 17th March 2026 is ₹30.97. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Rekvina Laboratories Ltd (VINRKLB) share?
The past returns of Rekvina Laboratories Ltd (VINRKLB) share are- Past 1 week: 3.58%
- Past 1 month: 33.55%
- Past 3 months: N/A%
- Past 6 months: 328.95%
- Past 1 year: 328.95%
- Past 3 years: N/A%
- Past 5 years: 328.95%
What are the peers or stocks similar to Rekvina Laboratories Ltd (VINRKLB)?
The peers or stocks similar to Rekvina Laboratories Ltd (VINRKLB) include:What is the market cap of Rekvina Laboratories Ltd (VINRKLB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Rekvina Laboratories Ltd (VINRKLB) is ₹18.31 Cr as of 17th March 2026.What is the 52 week high and low of Rekvina Laboratories Ltd (VINRKLB) share?
The 52-week high of Rekvina Laboratories Ltd (VINRKLB) is ₹30.49 and the 52-week low is ₹6.75.What is the PE and PB ratio of Rekvina Laboratories Ltd (VINRKLB) stock?
The P/E (price-to-earnings) ratio of Rekvina Laboratories Ltd (VINRKLB) is -130.76. The P/B (price-to-book) ratio is -53.84.Which sector does Rekvina Laboratories Ltd (VINRKLB) belong to?
Rekvina Laboratories Ltd (VINRKLB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Rekvina Laboratories Ltd (VINRKLB) shares?
You can directly buy Rekvina Laboratories Ltd (VINRKLB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Rekvina Laboratories Ltd
VINRKLB Share Price
BSEVINRKLB Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
VINRKLB Performance & Key Metrics
VINRKLB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -79.60 | -53.84 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.66 | 5.63 | 0.60% |
VINRKLB Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
VINRKLB Company Profile
Rekvina Laboratories is engaged in business of pharmaceuticals.
VINRKLB Forecast
VINRKLB Forecasts
VINRKLB
VINRKLB
Income
Balance Sheet
Cash Flow
VINRKLB Income Statement
VINRKLB Income Statement
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.35 | ||||||||||
| Operating & Other expenses | 0.01 | 0.00 | 0.00 | 0.00 | 0.07 | 0.02 | 0.04 | 0.04 | 0.23 | 0.47 | ||||||||||
| EBITDA | -0.01 | 0.00 | 0.00 | 0.00 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| PBIT | -0.01 | 0.00 | 0.00 | 0.00 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| PBT | -0.01 | 0.00 | 0.00 | 0.00 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Net Income | -0.01 | 0.00 | 0.00 | 0.00 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | ||||||||||
| EPS | -0.02 | -0.01 | 0.00 | -0.01 | -0.11 | -0.04 | -0.07 | 0.05 | 0.06 | -0.21 |
VINRKLB Company Updates
VINRKLB Stock Peers
VINRKLB Past Performance & Peer Comparison
VINRKLB Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Rekvina Laboratories Ltd | -130.76 | -53.84 | — |
| Sun Pharmaceutical Industries Ltd | 39.15 | 5.90 | 0.90% |
| Torrent Pharmaceuticals Ltd | 75.55 | 19.02 | 0.75% |
| Dr Reddy's Laboratories Ltd | 18.80 | 3.13 | 0.63% |
VINRKLB Stock Price Comparison
Compare VINRKLB with any stock or ETFVINRKLB Holdings
VINRKLB Shareholdings
VINRKLB Promoter Holdings Trend
VINRKLB Promoter Holdings Trend
VINRKLB Institutional Holdings Trend
VINRKLB Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
VINRKLB Shareholding Pattern
VINRKLB Shareholding Pattern
VINRKLB Shareholding History
VINRKLB Shareholding History
smallcases containing VINRKLB stock
smallcases containing VINRKLB stock
Looks like this stock is not in any smallcase yet.
VINRKLB Events
VINRKLB Events
VINRKLB Dividend Trend
VINRKLB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
VINRKLB Dividend Trend
VINRKLB has not given any dividends in last 5 years
VINRKLB Dividends
VINRKLB Dividends
VINRKLB Stock News & Opinions
VINRKLB Stock News & Opinions
Rekvina Labs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 April 2026.Powered by Capital Market - Live
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 16 March 2026.Powered by Capital Market - Live
Net Loss of Rekvina Labs reported to Rs 0.12 crore in the quarter ended December 2025 as against net loss of Rs 0.02 crore during the previous quarter ended December 2024. Sales reported to Rs 0.35 crore in the quarter ended December 2025. There were no Sales reported during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales0.350 0 OPM %-34.290 - PBDT-0.12-0.02 -500 PBT-0.12-0.02 -500 NP-0.12-0.02 -500 Powered by Capital Market - Live
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live
Net loss of Rekvina Labs reported to Rs 0.02 crore in the quarter ended December 2024. There were no net profit/loss reported during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 20 January 2025.Powered by Capital Market - Live
Net Loss of Rekvina Labs reported to Rs 0.07 crore in the quarter ended September 2024 as against net loss of Rs 0.01 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Rekvina Labs announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Rekvina Labs has revised the meeting of the Board of Directors which was scheduled to be held on 30 August 2024. The meeting will now be held on 2 September 2024.Powered by Capital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant